Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free CMPX Stock Alerts

Compass Therapeutics (CMPX) Financials

Compass Therapeutics logo
$1.84 -0.11 (-5.38%)
Closing price 03:59 PM Eastern
Extended Trading
$1.85 +0.01 (+0.49%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Compass Therapeutics

Annual Income Statements for Compass Therapeutics

This table shows Compass Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -35 -30 -82 -39 -42 -49 -66
Consolidated Net Income / (Loss)		 -35 -30 -82 -39 -42 -49 -66
Net Income / (Loss) Continuing Operations		 -35 -30 -82 -39 -42 -49 -66
Total Pre-Tax Income 		-35 -29 -82 -39 -42 -49 -66
Total Operating Income		 -34 -28 -82 -42 -50 -57 -73
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.85 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.85 0.00
Operating Revenue		 - - - - 0.00 0.85 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 34 28 82 42 50 57 73
Selling, General & Admin Expense		 12 13 11 12 12 15 17
Research & Development Expense		 22 15 71 30 38 42 56
Total Other Income / (Expense), net		 -0.60 -1.66 -0.30 2.43 7.87 7.25 6.35
Other Income / (Expense), net		 0.63 -1.66 -0.30 2.43 7.87 7.25 6.35
Basic Earnings per Share		 ($5.19) ($0.96) ($1.31) ($0.37) ($0.33) ($0.36) ($0.42)
Weighted Average Basic Shares Outstanding		 6.69M 30.78M 62.87M 105.19M 127.03M 137.38M 157.70M
Weighted Average Diluted Shares Outstanding		 6.69M 30.78M 62.87M 126.51M 137.59M 138.28M 180.09M
Weighted Average Basic & Diluted Shares Outstanding		 6.69M 30.78M 62.87M 126.51M 137.59M 138.28M 180.09M

Quarterly Income Statements for Compass Therapeutics

This table shows Compass Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -11 -9.96 -13 -11 -13 -10 -15 -17 -20 -14 -16
Consolidated Net Income / (Loss)		 -11 -9.96 -13 -11 -13 -10 -15 -17 -20 -14 -16
Net Income / (Loss) Continuing Operations		 -11 -9.96 -13 -11 -13 -10 -15 -17 -20 -14 -16
Total Pre-Tax Income 		-11 -9.96 -13 -11 -13 -10 -15 -17 -20 -14 -16
Total Operating Income		 -13 -12 -15 -13 -15 -12 -17 -18 -21 -16 -18
Total Operating Expenses		 13 12 15 13 16 12 17 18 21 16 18
Selling, General & Admin Expense		 3.11 3.10 2.96 3.25 4.72 3.63 3.54 4.91 4.65 2.99 4.32
Research & Development Expense		 10 8.83 12 9.52 11 8.61 13 13 16 13 14
Total Other Income / (Expense), net		 2.06 1.96 1.97 1.98 1.97 1.76 1.54 1.33 1.19 1.56 2.27
Other Income / (Expense), net		 2.06 1.96 1.97 1.98 1.97 1.76 1.54 1.33 1.19 1.56 2.27
Basic Earnings per Share		 ($0.09) ($0.08) ($0.10) ($0.08) ($0.10) ($0.08) ($0.10) ($0.12) ($0.14) ($0.08) ($0.08)
Weighted Average Basic Shares Outstanding		 126.73M 127.42M 127.03M 136.61M 137.59M 137.59M 137.38M 138.24M 138.28M 168.78M 157.70M
Weighted Average Diluted Shares Outstanding		 127.46M 127.49M 137.59M 137.59M 137.59M 137.59M 138.28M 138.28M 138.28M 177.86M 180.09M
Weighted Average Basic & Diluted Shares Outstanding		 127.46M 127.49M 137.59M 137.59M 137.59M 137.59M 138.28M 138.28M 138.28M 177.86M 180.09M

Annual Cash Flow Statements for Compass Therapeutics

This table details how cash moves in and out of Compass Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -32 22 97 -110 -11 19 -13
Net Cash From Operating Activities		 -32 -27 -20 -34 -41 -45 -49
Net Cash From Continuing Operating Activities		 -32 -27 -20 -34 -41 -45 -49
Net Income / (Loss) Continuing Operations		 -35 -30 -82 -39 -42 -49 -66
Consolidated Net Income / (Loss)		 -35 -30 -82 -39 -42 -49 -66
Depreciation Expense		 2.12 2.40 0.57 0.78 0.70 0.59 0.28
Amortization Expense		 - 0.00 1.06 0.32 -2.04 -0.49 -0.48
Non-Cash Adjustments To Reconcile Net Income		 1.14 4.94 54 4.16 4.92 7.34 8.00
Changes in Operating Assets and Liabilities, net		 -0.25 -4.65 7.36 -0.16 -1.71 -2.93 9.55
Net Cash From Investing Activities		 -0.47 0.04 -1.77 -151 27 47 -93
Net Cash From Continuing Investing Activities		 -0.47 0.04 -1.77 -151 27 47 -93
Purchase of Property, Plant & Equipment		 -0.47 -0.11 -1.57 -0.21 -0.03 -0.04 -0.03
Purchase of Investments		 - - 0.00 -200 -155 -88 -195
Sale and/or Maturity of Investments		 - - 0.00 49 182 135 101
Net Cash From Financing Activities		 0.00 49 119 76 2.94 17 130
Net Cash From Continuing Financing Activities		 0.00 49 119 76 2.94 17 130
Repurchase of Common Equity		 0.00 -6.32 -0.28 -0.50 -0.09 -0.54 -8.64
Issuance of Common Equity		 0.00 60 128 76 3.13 18 138
Other Financing Activities, net		 - - 0.00 0.02 -0.10 -0.23 0.25

Quarterly Cash Flow Statements for Compass Therapeutics

This table details how cash moves in and out of Compass Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 -7.75 11 -6.20 -0.55 -4.27 18 6.11 -2.44 -18 23 -16
Net Cash From Operating Activities		 -10 -5.92 -12 -14 -11 -11 -9.16 -13 -12 -11 -13
Net Cash From Continuing Operating Activities		 -10 -5.92 -12 -14 -11 -11 -9.16 -13 -12 -11 -13
Net Income / (Loss) Continuing Operations		 -11 -9.96 -13 -11 -13 -10 -15 -17 -20 -14 -16
Consolidated Net Income / (Loss)		 -11 -9.96 -13 -11 -13 -10 -15 -17 -20 -14 -16
Depreciation Expense		 0.18 0.16 0.16 0.15 0.15 0.14 0.14 0.14 0.10 0.02 0.02
Amortization Expense		 -0.74 -0.48 -0.51 -0.07 -0.41 0.04 -0.05 0.25 0.14 -0.02 -0.84
Non-Cash Adjustments To Reconcile Net Income		 1.33 1.32 1.29 1.68 1.80 2.20 1.66 2.26 2.75 1.20 1.79
Changes in Operating Assets and Liabilities, net		 0.40 3.04 0.12 -4.87 0.79 -2.96 4.12 0.77 5.06 2.21 1.50
Net Cash From Investing Activities		 -0.67 17 6.31 -4.10 6.48 29 15 12 -6.36 -95 -3.38
Net Cash From Continuing Investing Activities		 -0.67 17 6.31 -4.10 6.48 29 15 12 -6.36 -95 -3.38
Purchase of Investments		 -38 -17 -45 -42 -31 -5.35 -9.86 -25 -33 -109 -27
Sale and/or Maturity of Investments		 37 34 51 38 38 34 25 36 27 14 24
Net Cash From Financing Activities		 3.03 0.02 -0.16 17 0.00 -0.00 -0.09 -0.82 - 129 1.06
Net Cash From Continuing Financing Activities		 3.03 0.02 -0.16 17 0.00 -0.00 -0.09 -0.82 - 129 1.06
Other Financing Activities, net		 - 0.02 -0.16 -0.14 - - -0.10 -0.82 - - 1.06

Annual Balance Sheets for Compass Therapeutics

This table presents Compass Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2018 3/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.00 0.00 52 154 200 157 140 220
Total Current Assets		 0.00 0.00 50 147 195 154 133 210
Cash & Equivalents		 0.00 0.00 47 145 35 24 43 31
Restricted Cash		 - - - - - - 0.57 0.57
Short-Term Investments		 - - - 0.00 152 128 83 178
Prepaid Expenses		 - - 3.13 2.59 8.18 1.42 6.03 0.91
Plant, Property, & Equipment, net		 0.00 0.00 1.13 2.24 1.57 0.90 0.35 0.10
Total Noncurrent Assets		 0.00 0.00 0.58 4.41 3.29 2.10 6.73 9.10
Other Noncurrent Operating Assets		 - - 0.58 4.41 3.29 2.10 6.73 9.10
Total Liabilities & Shareholders' Equity		 0.00 0.00 52 154 200 157 140 220
Total Liabilities		 0.03 0.08 12 14 18 8.34 15 23
Total Current Liabilities		 0.03 0.08 10 11 16 7.80 8.87 14
Accounts Payable		 0.00 0.00 1.06 0.87 3.38 4.09 2.25 1.59
Accrued Expenses		 - - 1.57 8.78 12 2.51 6.29 11
Other Current Liabilities		 - - 0.00 0.99 1.10 - 0.34 1.00
Total Noncurrent Liabilities		 0.00 0.00 1.87 3.05 1.84 0.54 6.30 8.83
Other Noncurrent Operating Liabilities		 - - 0.00 3.05 1.84 0.54 6.30 8.83
Commitments & Contingencies		 - - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -0.03 -0.07 40 140 182 149 125 197
Total Preferred & Common Equity		 -0.03 -0.07 40 140 182 149 125 197
Total Common Equity		 -0.03 -0.07 40 140 182 149 125 197
Common Stock		 0.00 0.00 191 374 455 464 490 628
Retained Earnings		 -0.04 -0.07 -151 -234 -273 -315 -365 -431
Accumulated Other Comprehensive Income / (Loss)		 - - - 0.00 -0.30 0.04 0.21 0.28

Quarterly Balance Sheets for Compass Therapeutics

This table presents Compass Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 179 170 161 156 149 131 117 231
Total Current Assets		 175 167 159 154 141 124 106 221
Cash & Equivalents		 19 30 24 19 37 41 23 46
Restricted Cash		 - - - - - 0.57 0.57 0.57
Short-Term Investments		 149 133 133 127 99 72 78 174
Prepaid Expenses		 6.52 2.88 2.36 7.32 5.74 12 5.25 1.23
Plant, Property, & Equipment, net		 1.20 1.05 0.74 0.59 0.49 0.23 0.13 0.12
Total Noncurrent Assets		 2.71 2.40 1.79 1.47 7.52 6.51 9.80 9.45
Other Noncurrent Operating Assets		 2.71 2.40 1.79 1.47 7.52 6.51 9.80 9.45
Total Liabilities & Shareholders' Equity		 179 170 161 156 149 131 117 231
Total Liabilities		 11 9.99 4.08 9.51 11 21 23 22
Total Current Liabilities		 9.70 9.12 3.89 9.51 4.43 15 14 12
Accounts Payable		 0.72 2.31 0.85 1.19 0.96 1.58 2.60 3.10
Accrued Expenses		 7.83 5.64 1.82 7.23 2.92 13 11 8.68
Other Current Liabilities		 - - - - 0.56 0.11 0.27 0.63
Total Noncurrent Liabilities		 1.20 0.87 0.19 0.00 6.32 6.27 9.63 9.23
Other Noncurrent Operating Liabilities		 1.20 0.87 0.19 0.00 6.32 6.27 9.63 9.23
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 168 160 157 146 138 110 93 210
Total Preferred & Common Equity		 168 160 157 146 138 110 93 210
Total Common Equity		 168 160 157 146 138 110 93 210
Common Stock		 461 462 483 485 488 491 494 625
Retained Earnings		 -292 -302 -326 -339 -350 -381 -401 -415
Accumulated Other Comprehensive Income / (Loss)		 -0.51 -0.43 -0.09 -0.09 0.49 0.19 0.21 0.27

Annual Metrics And Ratios for Compass Therapeutics

This table displays calculated financial ratios and metrics derived from Compass Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 5,000,000.00 52,123,374.00 98,031,565.00 126,191,473.00 127,486,326.00 - 177,862,102.00
DEI Adjusted Shares Outstanding		 5,000,000.00 52,123,374.00 98,031,565.00 126,191,473.00 127,486,326.00 - 177,862,102.00
DEI Earnings Per Adjusted Shares Outstanding		 -6.95 -0.57 -0.84 -0.31 -0.33 - -0.37
Growth Metrics		 - - - - - - -
Profitability Metrics		 - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -24 -19 -57 -29 -35 -40 -51
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -23.54% -31.57% -25.91%
Earnings before Interest and Taxes (EBIT)		 -33 -29 -82 -39 -42 -49 -66
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -31 -27 -81 -38 -44 -49 -67
Valuation Ratios		 - - - - - - -
Leverage & Solvency		 - - - - - - -
Liquidity Ratios		 - - - - - - -
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -22 -51 -29 -37 -41 -40
Efficiency Ratios		 - - - - - - -
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -0.00 2.20 -4.44 -4.97 -2.73 -1.15 -13
Increase / (Decrease) in Invested Capital		 0.00 2.21 -6.64 -0.54 2.25 1.58 -11
Book Value per Share		 ($0.01) $0.77 $1.43 $1.44 $1.17 $0.91 $1.11
Tangible Book Value per Share		 ($0.01) $0.77 $1.43 $1.44 $1.17 $0.91 $1.11
Total Capital		 0.00 49 140 182 150 126 197
Total Debt		 0.07 9.33 0.00 0.00 1.20 0.34 0.00
Total Long-Term Debt		 0.00 1.87 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.07 -38 -145 -187 -151 -126 -209
Capital Expenditures (CapEx)		 0.47 -0.04 1.45 0.04 0.03 0.04 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.00 0.49 -8.04 -7.99 -5.18 -2.51 -14
Debt-free Net Working Capital (DFNWC)		 0.00 48 136 179 147 124 196
Net Working Capital (NWC)		 -0.07 40 136 179 146 124 196
Net Nonoperating Expense (NNE)		 11 10 25 10 7.24 9.74 16
Net Nonoperating Obligations (NNO)		 0.07 -38 -145 -187 -151 -126 -209
Total Depreciation and Amortization (D&A)		 2.12 2.40 1.62 1.10 -1.34 0.10 -0.20
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 ($0.01) $0.00 ($1.31) ($0.37) ($0.33) ($0.36) ($0.42)
Adjusted Weighted Average Basic Shares Outstanding		 5M 0.00 101.30M 105.19M 127.03M 137.38M 157.70M
Adjusted Diluted Earnings per Share		 ($0.01) $0.00 ($1.31) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 5M 0.00 101.30M 126.51M 137.59M 138.28M 180.09M
Adjusted Basic & Diluted Earnings per Share		 ($0.01) $0.00 ($1.31) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 5M 0.00 62.87M 126.51M 137.59M 138.28M 180.09M
Normalized Net Operating Profit after Tax (NOPAT)		 -24 -19 -57 -29 -35 -40 -51
Debt Service Ratios		 - - - - - - -
Payout Ratios		 - - - - - - -

Quarterly Metrics And Ratios for Compass Therapeutics

This table displays calculated financial ratios and metrics derived from Compass Therapeutics' official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
DEI Shares Outstanding		 126,507,473.00 127,459,346.00 127,486,326.00 137,589,171.00 137,589,171.00 137,589,171.00 - 138,282,498.00 138,282,498.00 138,282,498.00 177,862,102.00
DEI Adjusted Shares Outstanding		 126,507,473.00 127,459,346.00 127,486,326.00 137,589,171.00 137,589,171.00 137,589,171.00 - 138,282,498.00 138,282,498.00 138,282,498.00 177,862,102.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.09 -0.08 -0.11 -0.08 -0.10 -0.08 - -0.12 -0.14 -0.10 -0.09
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -9.34 -8.35 -11 -8.94 -11 -8.57 -12 -13 -15 -11 -13
Return On Investment Capital (ROIC_SIMPLE)		 - - -7.19% -5.65% -7.15% -6.19% -9.24% -11.40% -15.82% -5.28% -6.40%
Earnings before Interest and Taxes (EBIT)		 -11 -9.96 -13 -11 -13 -10 -15 -17 -20 -14 -16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -12 -10 -14 -11 -13 -10 -15 -16 -20 -14 -17
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -14 -10 -13 -11 -11 -14 -13 -7.62 -5.47 2.77 -1.97
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.68 -2.48 -2.73 2.03 0.97 3.00 -1.15 -2.92 -8.31 -11 -13
Increase / (Decrease) in Invested Capital		 4.72 2.00 2.25 1.93 0.28 5.48 1.58 -4.95 -9.28 -14 -11
Book Value per Share		 $1.33 $1.26 $1.17 $1.14 $1.06 $1.01 $0.91 $0.80 $0.67 $1.52 $1.11
Tangible Book Value per Share		 $1.33 $1.26 $1.17 $1.14 $1.06 $1.01 $0.91 $0.80 $0.67 $1.52 $1.11
Total Capital		 169 161 150 158 147 138 126 110 93 210 197
Total Debt		 1.15 1.17 1.20 1.22 1.09 0.00 0.34 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -168 -163 -151 -155 -145 -135 -126 -113 -102 -220 -209
Capital Expenditures (CapEx)		 0.00 0.01 0.01 0.00 0.00 0.04 0.00 0.02 0.00 0.01 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.03 -5.07 -5.18 -0.31 -1.10 1.31 -2.51 -3.96 -9.18 -12 -14
Debt-free Net Working Capital (DFNWC)		 167 159 147 156 145 137 124 109 92 209 196
Net Working Capital (NWC)		 166 157 146 155 144 137 124 109 92 209 196
Net Nonoperating Expense (NNE)		 1.94 1.62 2.64 1.85 2.54 1.91 3.43 4.06 5.13 3.19 3.12
Net Nonoperating Obligations (NNO)		 -168 -163 -151 -155 -145 -135 -126 -113 -102 -220 -209
Total Depreciation and Amortization (D&A)		 -0.56 -0.32 -0.34 0.09 -0.26 0.19 0.09 0.39 0.24 -0.00 -0.83
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.09) ($0.08) ($0.10) ($0.08) ($0.10) ($0.08) ($0.10) ($0.12) ($0.14) ($0.08) ($0.08)
Adjusted Weighted Average Basic Shares Outstanding		 126.73M 127.42M 127.03M 136.61M 137.59M 137.59M 137.38M 138.24M 138.28M 168.78M 157.70M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 127.46M 127.49M 137.59M 137.59M 137.59M 137.59M 138.28M 138.28M 138.28M 177.86M 180.09M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 127.46M 127.49M 137.59M 137.59M 137.59M 137.59M 138.28M 138.28M 138.28M 177.86M 180.09M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.34 -8.35 -11 -8.94 -11 -8.57 -12 -13 -15 -11 -13
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Financials Breakdown Chart

Key Financial Trends

Here are key takeaways from Compass Therapeutics' latest quarterly filings. These points cover the last four years of CMPX's quarterly statements and focus on liquidity, funding, and profitability signals for retail investors.

  • CMPX raised about $138 million via common equity issuances in Q1 2025, and another about $138 million in Q3 2025, substantially boosting liquidity.
  • In Q3 2025 the company posted a large net cash inflow from continuing financing activities of about $129.361 million, helping fund ongoing development.
  • Investing activities in 2025 included meaningful cash inflows from sale/maturity of investments (Q3 about $13.928 million; Q4 about $24.097 million), adding liquidity.
  • As of Q3 2025, CMPX had roughly $46.212 million in cash and equivalents, providing near-term liquidity runway.
  • Total equity was about $209.613 million in Q3 2025, reflecting a capital base built through funding activities.
  • Debt load is low in recent periods (short-term debt around $1.088 million in Q2 2025), indicating minimal leverage.
  • Net income remained negative, with CMPX reporting -$15.716 million in Q4 2025 and -$14.259 million in Q3 2025.
  • Cash flow from operating activities has been negative in every quarter, signaling ongoing cash burn (examples: Q4 2025 CFO about -$13.254 million; Q3 2025 CFO about -$10.849 million).
  • Retained earnings were negative by about -$415.456 million in Q3 2025, indicating substantial cumulative losses.
  • CMPX relies heavily on equity fundraising to finance operations, which results in significant dilution for common shareholders.
05/06/26 11:40 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Compass Therapeutics' Financials

When does Compass Therapeutics' financial year end?

According to the most recent income statement we have on file, Compass Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has Compass Therapeutics' net income changed over the last 6 years?

Compass Therapeutics' net income appears to be on an upward trend, with a most recent value of -$66.49 million in 2025, rising from -$34.74 million in 2019. The previous period was -$49.38 million in 2024. Check out Compass Therapeutics' forecast to explore projected trends and price targets.

What is Compass Therapeutics' operating income?
Compass Therapeutics' total operating income in 2025 was -$72.84 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $72.84 million
How has Compass Therapeutics' revenue changed over the last 6 years?

Over the last 6 years, Compass Therapeutics' total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

How much debt does Compass Therapeutics have?

Compass Therapeutics' total liabilities were at $22.80 million at the end of 2025, a 50.3% increase from 2024, and a 65,831.1% increase since 2018.

How much cash does Compass Therapeutics have?

In the past 7 years, Compass Therapeutics' cash and equivalents has ranged from $0.00 in 2018 to $144.51 million in 2021, and is currently $30.64 million as of their latest financial filing in 2025.

How has Compass Therapeutics' book value per share changed over the last 6 years?

Over the last 6 years, Compass Therapeutics' book value per share changed from -0.01 in 2019 to 1.11 in 2025, a change of -7,946.8%.


Related Companies

Financial statements for NASDAQ:CMPX last updated on 4/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?
BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...
Awesomely, LLC | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
The Iran War Just Broke the Gold Market
The Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...
Behind the Markets | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Gold surged 600 dollars last time this indicator peaked
The Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...
Porter & Company | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel